SCHEMBL3524294

SCHEMBL3524294

CCC(Oc1ccc(C#N)c(Cl)c1)c1sc(-c2ccc(C(F)(F)F)nc2)nc1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 7/20 0.36
PPARA Q07869 3/20 0.36
XDH P47989 2/20 0.35
ABCC4 O15439 1/20 0.35
ABCB11 O95342 1/20 0.35
PGR P06401 1/20 0.35
CHRM1 P11229 1/20 0.35
PDE4A P27815 1/20 0.35
BLVRB P30043 1/20 0.35
TARBP2 Q15633 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
ABCG2 Q9UNQ0 1/20 0.35
NR3C1 P04150 1/20 0.35
CYP11B2 P19099 4/20 0.34
CYP11B1 P15538 3/20 0.34
SLC22A12 Q96S37 2/20 0.33
ALPL P05186 1/20 0.33
ALPI P09923 1/20 0.33
SCN9A Q15858 2/20 0.33
PPID Q08752 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3529637 0.90 PPARD (0.37) PPARDCYP11B2SLC22A12
SCHEMBL3524928 0.81 PPARD (0.45) PPARDPPARA
SCHEMBL3530081 0.80 FNTA (0.37) XDHABCC4ABCB11PGRCHRM1
SCHEMBL3530076 0.79 CYP11B2 (0.34) PPARDXDHABCC4ABCB11PGR
SCHEMBL3530903 0.79 AR (0.35) PPARDPPARAXDHABCC4ABCB11
SCHEMBL3531920 0.79 PTGES (0.35) PPARDPPARA
SCHEMBL3530663 0.79 PPARD (0.33) PPARDPPARAXDHABCC4ABCB11
SCHEMBL3530670 0.79 FNTA (0.35) XDHABCC4ABCB11PGRCHRM1
SCHEMBL3738825 0.78 PPARD (0.46) PPARDPPARA
SCHEMBL3747883 0.77 PPARD (0.44) PPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1931337-B1 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2013-10-23 EP disclosed
US-7709481-B2 Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and methods for their use as pharmaceuticals SANOFI-AVENTIS (FR) 2010-05-04 US disclosed
US-20080261979-A1 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals SANOFI-AVENTIS (FR) 2008-10-23 US disclosed
EP-1931337-A2 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2008-06-18 EP disclosed
WO-2007039177-A2 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261979-A1 Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals PPARD, PPARA, PPARG PPARD 1/4885PPARA 2/4885XDH 1949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.